Skip to content
Research/Cognitive Enhancement/Low-Dose Aripiprazole

Low-Dose Aripiprazole

Aripiprazole, typically used as an antipsychotic, is being explored at low doses for potential cognitive enhancement and mood stabilization. Its mechanism involves partial agonism of dopamine D2 and serotonin 5-HT1A receptors, which may support cognitive function and emotional regulation. This could be relevant for longevity by potentially improving mental health and cognitive resilience.

Intelligence Profile

Clinical Applications

Low-dose aripiprazole is used for various psychiatric and neurological conditions. The following summarizes findings related to its clinical applications:

Post-traumatic Brain Injury and Bipolar-Spectrum Disorder: One study (PMID: 42125501) outlines the use of low-dose aripiprazole for managing bipolar-spectrum disorder post-traumatic brain injury. It explores phases like induction, stabilization, and maintenance. Although the study highlights a regimen involving glutamatergic augmentation, it underscores aripiprazole's role in long-term management.

Pediatric Use: Research (PMID: 42101110) reviews the use of antipsychotics in children and adolescents. While not specific to low doses, it indicates the use of aripiprazole among this population, suggesting potential application for behavioral and emotional regulation in younger patients.

Obsessive-Compulsive Disorder (OCD): Although indirectly related, a study (PMID: 41783550) mentions significant improvement in treatment-resistant OCD with a glutamatergic regimen. This indicates the potential for aripiprazole's use in augmentation therapies for OCD, though additional evidence specifically for low-dose use is needed.

Schizophrenia Treatment: Multiple clinical trials explore aripiprazole's efficacy in schizophrenia, including a Phase 4 trial (NCT01164059) comparing newer antipsychotics with conventional ones, suggesting its effectiveness in reducing acute schizophrenia symptoms.

Psychosis in Adolescents: The case of a 47,XXX adolescent with psychosis (PMID: 42036753) adds to the understanding of aripiprazole’s applications across varied psychiatric conditions, although specific dosing details are absent.

Overall, while low-dose aripiprazole shows promise in managing bipolar-spectrum disorders and potential in pediatric applications, specific low-dose-focused studies are limited. Its broader role in treating schizophrenia and potential co-therapeutic role in OCD warrant further investigation.

Disclaimer: This summary is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized care.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.